Bio Green Med Solution, Inc.

Item 1. Legal Proceedings

On or about May 13, 2026, David Lazar (“Lazar”), a self-described activist investor and former interim CEO of Cyclacel Pharmaceuticals, Inc., brought an action in the Supreme Court of the State of New York, New York County, against Datuk Dr. Doris Wong Sing Ee, the current CEO and Executive Director of Bio Green Med Solution, Inc., f/k/a Cyclacel Pharmaceuticals, Inc. (the “Company”), Kiu Cu Seng, Kwang Fock Chong, Inigo Angel Laurduraj, and Dr. Satis Waran Nair Krishnan, all of whom are members of the Board of Directors of the Company, titled David Lazar v. Datuk Dr. Doris Wong Sing Ee, Kiu Cu Seng, Kwang Fock Chong, Inigo Angel Laurduraj, and Dr. Satis Waran Nair Krishnan, Index No. 652797/2026 (the “2026 Action”). The Company is not a party to the 2026 Action. The 2026 Action alleges two causes of action for breach of fiduciary duty and seeks damages in the total amount of approximately $12 million. All defendants have moved to dismiss the 2026 Action, which motion is currently sub judice. The Company believes the 2026 Action is without merit. All defendants in the 2026 Action are covered under the Company’s directors’ and officers’ liability insurance policy.

On or about September 2, 2025, Lazar brought a separate action in the Supreme Court of the State of New York, New York County, against Datuk Dr. Doris Wong Sing Ee, titled David Lazar v. Datuk Dr. Doris Wong Sing Ee, Index No. 655184/2025 (the “2025 Action”). The Company is not a party to the 2025 Action. The complaint alleged four causes of action: breach of contract, breach of implied covenant of good faith and fair dealing, conversion, and unjust enrichment, and seeks damages in the total amount of $629,501.36. The defendant brought a motion to dismiss, pursuant to which the Court dismissed all causes of action except the first cause of action for breach of contract. The defendant is currently appealing the denial of the motion to dismiss that cause of action. The 2025 Action is in the early stages of discovery. The Company believes the 2025 Action is without merit. Wong is covered under the Company’s directors’ and officers’ liability insurance policy.

The Company does not believe that the ultimate resolution of these matters will have a material adverse effect on its financial condition, results of operations, or cash flows; however, litigation is inherently uncertain and there can be no assurance that these matters will be resolved favorably. No amounts have been accrued for these matters as of the date of this filing, as the Company has determined that a loss is not probable.